Patients with type 2 diabetes who use GLP-1 receptor agonists have a significantly lower risk for lung cancer than those who ...

CureGene Pharmaceuticals ("CureGene") today announced the first disclosure of groundbreaking preclinical data for CG-0416, a ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

This third of five exclusive episodes explores how clinicians can navigate newly approved MASH therapies -- resmetirom (Rezdiffra) and semaglutide (Wegovy) -- and how to tailor treatment choices based ...

CVOT, notable for comparing the two drugs, tirzepatide showed significantly greater improvements in major kidney outcomes vs dulaglutide.

Shares of Amgen are up nearly 26% this year and have soared 11% just over the past week.

At the beginning of the quarter, Virtus liquidated its position in Novo Nordisk (NVO) and used the proceeds to fund a new ...

WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...

Eli Lilly and Company’s LLY stock has risen 18% in a month, driven mainly by a stellar third-quarter performance. Also, ...

Significant improvements observed in secondary endpoints, including reductions in liver fat, inflammation and biomarkers of fibrosis GAITHERSBURG, Md., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc ...

A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...